AlphAIAlphAI — Financial news for AI agents
aol.comOCT 82 min read$EGHT

8x8 Names Jamie Snaddon Chief Strategy Officer

8x8, Inc. (NASDAQ: EGHT) appointed Jamie Snaddon as Chief Strategy Officer to drive growth and strategy. Snaddon, previously EMEA Managing Director, will focus on leveraging 8x8's technology and customer base. Nerea Gandarias succeeds him as EMEA Managing Director, bringing extensive regional experience.

Original reporting
aol.com
Published Oct 8, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 2:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$EGHT
Neutral
medium confidence
Mentioned
$EGHT
Relevance
7/10
AlphAI data visualization · based on aol.com
Decision brief

The 30-second read

$EGHTNeutralLow
01

Why it matters

The new CSO role is intended to accelerate growth opportunities and strategic initiatives.

02

Market read

Leadership changes could influence 8x8's strategic direction and investor sentiment.

03

What to watch

Execution risk of the new strategy and competitive pressures in the UCaaS market.

Relevance 7/10Novelty 8/10Timing: effective immediately

Background

Press release announcing senior leadership appointments at 8x8.

Company-level read

Ticker impact

$EGHTNeutralMedium confidence
Context

8x8 announced the appointment of Jamie Snaddon as Chief Strategy Officer and Nerea Gandarias as Managing Director, EMEA.

Expected impact

likely modest upside as investors evaluate the new strategy leadership

Evidence & confidence

The CSO role signals focus on growth, but no immediate financial impact is evident.

Market effects

Sector

May highlight strategic focus within the cloud communications sector.

Regional

US market could see a slight reaction to the leadership change.

Global

Impact is limited primarily to 8x8 shareholders and related analysts.

Counterpoint

What could challenge this read

The appointment may not translate into performance and could distract from core operations.

Key entities

  • Company
    8x8, Inc.

    Provider of cloud communications and contact center solutions.

  • Executive
    Jamie Snaddon

    Named Senior Vice President and Chief Strategy Officer.

  • Executive
    Nerea Gandarias

    Named Managing Director, EMEA.

Read at source← All news

Related articles

AUG 4
$EGHTMed

8x8’s (NASDAQ:EGHT) Q2 CY2026: Beats On Revenue, Full

8x8 (NASDAQ:EGHT) reported Q2 CY2026 revenue of $190.2 million, up 4.9% year on year, beating Wall Street’s estimate. Next-quarter revenue guidance was $187.5 million at the midpoint, above analysts’ expectations. Non-GAAP EPS was $0.09, matching consensus. The article also cites billings of $188.8 million and a CAC payback of 488.7 months.

financialcontent.com4 min
AUG 4
$EGHTHigh

8x8, Inc. Reports Record Revenue in First Quarter of Fiscal Year 2027

8X8 INC /DE/ (EGHT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 8x8, Inc. Reports Record Revenue in First Quarter of Fiscal Year 2027 • Fifth consecutive quarter of year-over-year revenue growth • Record service revenue of $185 million and total revenue of $190 million • Adoption of AI solutions accelerates as customers use AI St

SEC EDGAR 8-K6 min
OCT 10
$RBLXMed

Roblox AI game maker has a catch, Morgan Stanley’s test shows

Roblox's stock has fallen 69% from its September 2025 high, closing at $44.58 on October 5, 2026. The decline follows safety and quality improvements that reduced player spending. Morgan Stanley maintains an Overweight rating with a $55 target, citing AI and game discovery as advantages. Analysts are split, with 17 Buys and 18 Holds or Sells.

finance.yahoo.com2 min
OCT 10
$MNKDMedAI 8/10

A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein.

MannKind (MNKD) presented clinical data at HFSA 2026 showing Furoscix ReadyFlow's comparable urine output to IV furosemide. The autoinjector delivers an 80 mg/mL dose in under 10 seconds, with 91.3% and 92.7% bioavailability in thigh and upper-arm injections, respectively. ReadyFlow received FDA approval in July 2026 for fluid overload treatment in heart failure or CKD patients.

stocktitan.net2 min